Search clinical trials for: Failed or are Intolerant to BCG Vaccine

Total 479479 results

LintonPharm Co.,Ltd.

Recruiting

Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

Bladder Cancer

China
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)

Non-muscle-invasive Bladder Cancer

United States
Swiss Group for Clinical Cancer Research

Recruiting

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Bladder Cancer

Switzerland
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial Carcinoma | Stage 0 Bladder Urothelial Carcinoma

United States
Scynexis, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Coccidioidomycosis | Invasive Pulmonary Aspergillosis | Allergic Bronchopulmonary Aspergillosis | Histoplasmosis | Chronic Pulmonary Aspergillosis | Blastomycosis | Invasive Candidiasis | Recurrent Vulvovaginal Candidiasis | Mucocutaneous Candidiasis | Other Emerging Fungi

United States, Spain, United Kingdom, Austria, Pakistan, South Africa, Germany, Netherlands
Pfizer

Active, not recruiting

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (CREST)

Non-muscle Invasive Bladder Cancer

China, United States, Spain, Belgium, Korea, Republic of, Australia, United Kingdom, Japan, France, Germany, Canada, Russian Federation, Poland, Italy
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Hoffmann-La Roche

Completed

A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy

HIV Infections

United States
National Cancer Institute (NCI)
Rutgers Cancer Institute of New Jersey

Completed

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Bladder Cancer

United States
Merck KGaA, Darmstadt, Germany

Completed

A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies

Psoriasis

United Kingdom
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy

Renal Cell Carcinoma

China
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Serbia, South Africa, Japan, Israel, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Austria, Ireland, Czech Republic, Hungary, Denmark, Icela...
Boehringer Ingelheim

Approved for marketing

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

HIV Infections

United States, Australia, Belgium, Denmark, France, Greece, Ireland, Italy, Portugal, South Africa, Switzerland, United Kingdom
Jennerex Biotherapeutics

Completed

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib (TRAVERSE)

HCC | Hepatocellular Carcinoma | Liver Cancer

Korea, Republic of, United States, Hong Kong, Canada, Germany, France, Taiwan
European Organisation for Research and Treatment...

Completed

Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer (SILVA)

Lung Cancer

United States, Spain, Australia, United Kingdom, Belgium, Germany, Switzerland, Netherlands, Austria, New Zealand
Novartis Pharmaceuticals

No longer available

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Metastatic Renal Cell Cancer

United States, United Kingdom, Czech Republic, Canada, Germany, Lebanon, Turkey, Hungary, Norway, Australia, Austria, Belgium, Switzerland
Hoffmann-La Roche

Completed

An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies

HIV Infections

United States
Glaxo Wellcome

Completed

A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine

HIV Infections | Toxoplasmosis, Cerebral

United States, Canada
Fujian Medical University Union Hospital

Recruiting

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms | Treatment Outcome | Neoplasm Recurrence, Local | Multicenter Study | Immunotherapy, Active | BCG Vaccine

China
Hookipa Biotech GmbH

Not yet recruiting

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

Human Immunodeficiency Virus (HIV) Infection

United States
Fudan University

Recruiting

Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients

Bladder Cancer

China
Ractigen Therapeutics.

Recruiting

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Australia
McGill University
Université de Montréal

Not yet recruiting

A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

Amyotrophic Lateral Sclerosis

Canada
University of Oxford

Recruiting

BCG Revaccination Study in Diabetic and Non-Diabetic Adults

Tuberculosis

United Kingdom
Fudan University

Not yet recruiting

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer | HER-2 Protein Overexpression
BioNTech SE
Pfizer

Recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

COVID-19 | Influenza

United States
South Australian Health and Medical Research Institute
University of Sydney; Telethon Kids Institute; Flinders University; Royal Adelaide... and other collaborators

Recruiting

Antibiotics and Vaccine Immune Responses Study (AVIRS)

Vaccine Response Impaired

Australia
Colorado Prevention Center
Bayer; Saint Luke's Hospital of Kansas City

Not yet recruiting

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)

Heart Failure
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); Biofabri, S.L

Recruiting

Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa (HVTN605A5421)

Tuberculosis | HIV I Infection

South Africa
Massachusetts General Hospital

Recruiting

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

Diabetes Mellitus | Type 1 Diabetes | Diabetes type1 | Autoimmune Diabetes

United States
Centre Hospitalier Universitaire Vaudois

Not yet recruiting

PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma (CHUV-OVACURE)

Ovarian Carcinoma
Assiut University

Not yet recruiting

Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume

Urothelial Carcinoma Bladder | Sperm Count, Low | Testis; Fibrosis
Bandim Health Project
University of Coimbra; University of Southern Denmark; Steno Diabetes Center... and other collaborators

Recruiting

Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau (BCGTODM)

Diabetes Mellitus | BCG Vaccination Reaction

Guinea-Bissau
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
BioNTech SE

Recruiting

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers

Tuberculosis

South Africa
International Maternal Pediatric Adolescent AIDS...
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaborators

Not yet recruiting

Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

HIV Infections | Tuberculosis

South Africa
Mansoura University

Recruiting

Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients

Non-Muscle Invasive Bladder Cancer

Egypt
Pfizer
National Heart, Lung, and Blood Institute (NHLBI); Carelon Research

Recruiting

A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.

Myocarditis

United States, Canada
Pfizer

Recruiting

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

COVID-19

United States, United Kingdom, Mexico, South Africa, Japan, Bulgaria, Hungary, Puerto Rico
Massachusetts General Hospital
NYU Langone Health

Recruiting

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes

Diabetes Mellitus, Type 1 | Diabetes type1 | Autoimmune Diabetes

United States
AbbVie

Recruiting

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Hidradenitis Suppurativa

United States, Australia, Canada, Germany, Greece, Japan, Spain, Puerto Rico
Verity Pharmaceuticals Inc.

Not yet recruiting

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (EVER)

Bladder Cancer | Urothelial Carcinoma Bladder | Bladder Cancer Recurrent | Neoplasm Recurrence | Urothelial Carcinoma Recurrent | Non-Invasive Bladder Urothelial Carcinoma
Pfizer

Recruiting

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (RENOIR)

Lower Respiratory Tract Illness

United States, Argentina, Canada, Finland, Japan, Netherlands, South Africa
Biofabri, S.L
University of Stellenbosch; University of Cape Town; TuBerculosis Vaccine Initiative and other collaborators

Recruiting

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa (MTBVACN3)

Tuberculosis

South Africa
Janssen Research & Development, LLC

Recruiting

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

United States, United Kingdom, Korea, Republic of, Taiwan, Canada, Denmark, France, Thailand, New Zealand, Spain, China, Israel, Germany, Colombia, India, Netherlands, Australia, Japan, Sweden, Czechia, Italy
Lee's Pharmaceutical Limited

Recruiting

Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Local Progression or Metastatic Melanoma With Failed First-line Treatment

China
Flemming Forsberg
National Cancer Institute (NCI)

Recruiting

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable...

United States, Norway
Jørgen Bjerggaard Jensen
Odense University Hospital; Karolinska University Hospital; Zealand University... and other collaborators

Recruiting

NORTH-REG Dwell-Time Study

Side Effect of Drug

Denmark, Sweden, Iceland
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1)

Non-squamous NSCLC | HER2 Exon 20 Mutation

Korea, Republic of, United States, Taiwan, Belgium, Spain, China, Australia, Turkey, Italy, France, Germany, Poland, Russian Federation

Search clinical trials for: Failed or are Intolerant to BCG Vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations